Tyrosine

Tyrosine

SCHEMBL6415645

C[C@@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)O.NC(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.56
MME P08473 1/20 0.55
ACE P12821 6/20 0.53
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
PTGS1 P23219 1/20 0.51
XIAP P98170 1/20 0.51
OPRD1 P41143 5/20 0.47
OPRM1 P35372 4/20 0.47
OPRK1 P41145 1/20 0.47
ANPEP P15144 2/20 0.47
ERAP2 Q6P179 2/20 0.47
ERAP1 Q9NZ08 2/20 0.47
LAP3 P28838 1/20 0.47
ENPEP Q07075 1/20 0.47
CPA1 P15085 1/20 0.46
CPA2 P48052 1/20 0.46
CPA4 Q9UI42 1/20 0.46
LTA4H P09960 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL7371902 1.00 SLC7A5 (0.56) SLC7A5MMEACEALPIPKM
Dl-Phenylalanine SCHEMBL6415329 0.94 ALPI (0.58) SLC7A5MMEACEALPIPKM
SCHEMBL6414438 0.93 MME (0.51) SLC7A5MMEACEOPRK1
Homophenylalanine SCHEMBL6419916 0.86 MME (0.53) MMEACE
Serine SCHEMBL6413334 0.84 MME (0.51) MMEACE
Alanine SCHEMBL6415193 0.84 MME (0.56) MMEACE
SCHEMBL5311806 0.83 MME (0.61) MMEACE
SCHEMBL7319806 0.83 MME (0.61) MMEACE
SCHEMBL3369279 0.83 MME (0.61) MMEACE
SCHEMBL4668246 0.83 MME (0.61) MMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020607-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2005-01-27 US disclosed
US-20040176393-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2004-09-09 US disclosed
EP-1366765-A1 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing WARNER-LAMBERT COMPANY LLC (US) 2003-12-03 EP disclosed
EP-1047450-B1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER LAMBERT CO (US) 2002-10-02 EP disclosed
US-20020049237-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2002-04-25 US disclosed
US-6340709-B1 ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE WARNER-LAMBERT COMPANY 2002-01-22 US disclosed
US-6133304-A TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR WARNER-LAMBERT COMPANY (US) 2000-10-17 US disclosed
US-5948780-A ADMINISTERING A METALLOPROTEINASE INHIBITOR WARNER-LAMBERT COMPANY (US) 1999-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176393-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 SLC7A5 1717/4885MME 174/4885ACE 52/4885
US-20050020607-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 SLC7A5 1717/4885MME 174/4885ACE 52/4885
US-20020049237-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 SLC7A5 1717/4885MME 174/4885ACE 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.